Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Rima I Ghamrawi"'
Autor:
Matthew L Hrin, Megan R Newsom, Rima I Ghamrawi, Angela G Niehaus, Steven R Feldman, Justin R Sigmon, Lindsay C Strowd
Publikováno v:
Journal of Dermatology and Dermatologic Surgery, Vol 25, Iss 2, Pp 54-58 (2021)
Background: Primary cutaneous gamma delta T cell lymphoma (PCGD TCL) is a rare and rapidly progressive cutaneous malignancy that can be diagnostically challenging. Purpose: To improve characterization of the clinical and histologic features of PCGD-T
Externí odkaz:
https://doaj.org/article/9e017e4a75c24cf88544b784303fc19a
Publikováno v:
European Medical Journal Dermatology, Vol 8, Iss 1, Pp 84-95 (2020)
With the recent advancements of biologic therapies that block IL-23, there is increasing need for analysis of which biologics are most efficacious in treatment of plaque psoriasis. Guselkumab and risankizumab have each individually been compared to a
Externí odkaz:
https://doaj.org/article/621f8f102c484f0283c6e04d7334b592
Publikováno v:
Pandher, K, Ghamrawi, R I, Heron, C E & Feldman, S R 2022, ' Controversial cardiovascular and hematologic comorbidities in atopic dermatitis ', Archives of Dermatological Research, vol. 314, no. 4, pp. 317-324 . https://doi.org/10.1007/s00403-021-02240-z
Atopic dermatitis’ (AD) systemic involvement is wide-reaching. The cardiovascular and hematological comorbidities of AD have potential for considerable economic and physical burden; however, data surrounding the association between these comorbidit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eae7f5762e55ae9e9be7444774c5e0f
https://doi.org/10.1007/s00403-021-02240-z
https://doi.org/10.1007/s00403-021-02240-z
Publikováno v:
Johnson, M C, Heron, C E, Ghamrawi, R I, Balogh, E A & Feldman, S R 2021, ' Speed of Psoriasis Treatment Response for Biologic Agents : A Review of Phase III Clinical Trials ', Journal of Psoriasis and Psoriatic Arthritis, vol. 6, no. 2, pp. 99-105 . https://doi.org/10.1177/2475530321999087
Background: Clinical trials often focus on the efficacy of biologic agents in the treatment of psoriasis without emphasis on the speed of response. Objective: We evaluated clinical trial data to determine which biologic agents achieve the fastest tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48452c2fde3ad677adf6e8ed55cd5610
https://doi.org/10.1177/2475530321999087
https://doi.org/10.1177/2475530321999087
Publikováno v:
Berg, S H, Balogh, E A, Ghamrawi, R I & Feldman, S R 2021, ' A review of secukinumab in psoriasis treatment ', Immunotherapy, vol. 13, no. 3, pp. 201-216 . https://doi.org/10.2217/imt-2020-0195
Psoriasis is a systemic immunologic disorder associated with decreased quality of life and numerous co-morbidities, including psoriatic arthritis and cardiovascular disease. Secukinumab, a fully human IgG1 monoclonal antibody, selectively binds IL-17
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45e1b6ef4ef7f11e593227f558b37de0
https://doi.org/10.2217/imt-2020-0195
https://doi.org/10.2217/imt-2020-0195
Autor:
Stephanie N. Snyder, Arjun M. Bashyam, Rima I. Ghamrawi, Deborah Cull, Emily L. Unrue, Wasim Haidari, Abigail E. Cline, Karl Wold, Sean McGregor, Steven R. Feldman
Publikováno v:
Journal of cutaneous medicine and surgery. 26(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::398a7157ddbcc545f99c0f224183e4be
https://pubmed.ncbi.nlm.nih.gov/35575451
https://pubmed.ncbi.nlm.nih.gov/35575451
Publikováno v:
Ghamrawi, R, Bell, K A, Balogh, E A, Strowd, L C & Feldman, S R 2020, ' Current and emerging biologics for the treatment of pediatric atopic dermatitis ', Expert Opinion on Biological Therapy, vol. 20, no. 12, pp. 1435-1445 . https://doi.org/10.1080/14712598.2021.1840548
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by erythematous lesions, pruritus, and a skin barrier defect. Long-term treatment in children is challenging, as there is only one Food and Drug Administratio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::794e4b41788dc5073f3c5a83a9143359
https://doi.org/10.1080/14712598.2021.1840548
https://doi.org/10.1080/14712598.2021.1840548
Publikováno v:
ImmunoTargets and Therapy. 9:255-272
Background Atopic dermatitis (AD) is a common chronic, inflammatory skin condition. The pathogenesis of AD involves many cytokines that utilize the Janus kinase/signal transducer and activator of transcription (JAK-STAT) signaling cascade; therefore,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2903918a8d1f4e069cbbebee12fd7210
https://doi.org/10.2147/itt.s229667
https://doi.org/10.2147/itt.s229667
Publikováno v:
Journal of Dermatological Treatment. 33:94-99
Purpose: This review article serves to compare global dermatologic organizations and the available clinical practice guidelines for the use of apremilast in the treatment of psoriasis.Materials and methods: Guidelines from the American Academy of Der
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7272396dc71e96fd5a78b81536c7304c
https://doi.org/10.1080/09546634.2020.1770176
https://doi.org/10.1080/09546634.2020.1770176
Publikováno v:
Svoboda, S A, Ghamrawi, R I, Owusu, D A & Feldman, S R 2020, ' Treatment Goals in Psoriasis : Which Outcomes Matter Most? ', American Journal of Clinical Dermatology, vol. 21, no. 4, pp. 505-511 . https://doi.org/10.1007/s40257-020-00521-3
Psoriasis is a chronic immune-mediated inflammatory disease that predominantly affects the skin and joints. Its detrimental effects on the physical, psychosocial, and emotional well-being of patients leads to a significant reduction in quality of lif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4faa9765cdafb7a21561600cf3444b01
https://doi.org/10.1007/s40257-020-00521-3
https://doi.org/10.1007/s40257-020-00521-3